Hepatitis C Virus

@article{Kim2016HepatitisCV,
  title={Hepatitis C Virus},
  author={A Young Kim},
  journal={Annals of Internal Medicine},
  year={2016},
  volume={165},
  pages={ITC33-ITC48}
}
  • A. Kim
  • Published 2016
  • Medicine
  • Annals of Internal Medicine
The advent of novel therapies has transformed the approach to patients with hepatitis C virus (HCV) infection. This virus is the most common blood-borne pathogen in the United States and is estimated to infect over 3 million Americans, most of whom were born from 1945 through 1965 (1, 2). It is a leading cause of morbidity and mortality, primarily through development of liver fibrosis and cirrhosis; persons with chronic infection live an average of 2 decades less than healthy persons (3… Expand
Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy
Since the 1960s, a single class of agent has been licensed targeting virus-encoded ion channels, or ‘viroporins’, contrasting the success of channel blocking drugs in other areas of medicine.Expand
Posttraumatic Stress Disorder in Opioid Agonist Therapy: A Review
TLDR
Given the high comorbidity of PTSD and OUD, many individuals in OAT have PTSD and continue to experience symptoms of both disorders despite OAT treatment. Expand
Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays
TLDR
This review aims to help blood bank staff regarding options for diagnosis and management of donors positive for HCV and how to establish or exclude a diagnosis of HCV infection and to interpret the tests correctly. Expand
Regulation of Autophagy in Cells Infected With Oncogenic Human Viruses and Its Impact on Cancer Development
TLDR
The current understanding of the molecular mechanisms by which human oncogenic viruses regulate autophagy and how this negative regulation impacts on cancer development is summarized and novel autophile-related candidates for the treatment of virus-related cancers are highlighted. Expand
Transcriptome and miRNome Analysis Provide New Insight Into Host Lipid Accumulation, Innate Immunity, and Viral Persistence in Hepatitis C Virus Infection in vitro
TLDR
Investigation of transcriptome and miRNome alterations in HCV-infected Huh7 cells at 12, 36, and 60 h after infection provided insight into host-directed mechanisms to control viral replication and presented a comprehensive expression profile of miRN as well as suggested deregulated genes directly regulated lipid metabolical genes at 60 h. Expand
Cluster of hepatitis C in a family: a twenty-year follow-up.
TLDR
A thorough epidemiological investigation of the two first generations of this family, the study of their spouses and children, and the twenty years of follow up provided a strong presumption that the infection with HCV had occurred within this family through the promiscuous use of the same inadequately sterilized glass syringe for intramuscular therapies, as was a common practice during the fifties and sixties worldwide and still is in some part of the world. Expand
The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases
TLDR
This is the first review regarding molecular and cellular pathways of the virus life cycle, treatment strategies, and therapeutic targets of several viral diseases with a particular focus on anthocyanins as promising natural compounds for significant antiviral enhancements. Expand
Plant-derived antivirals against hepatitis c virus infection
TLDR
This review aims to summarize the most promising plant-derived compounds described to have antiviral activity against HCV and indicates that plant- derived compounds can provide an alternative approach to new antivirals. Expand
Prevalencija pozitivnih markera hepatitisa B i C u osoba koje se uključuju u skrb zbog zaraze HIV-om u Hrvatskoj u razdoblju 2007.-2016.
Virus hepatitisa B (HBV), virus hepatitisa C (HCV) i virus humane imunodeficijencije (HIV) dijele zajednicke putove prijenosa, koji ukljucuju prijen
Real-world challenges for hepatitis C virus medications: a critical overview
TLDR
The challenges encountered while surmounting the burden of hepatitis C around the world are outlined, including therapy cost, treatment access to low and middle-income countries, treatment-emergent adverse events, lack of effective viral screening and disease progression simulation models are potential challenges. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus.
  • Fujie Xu, A. Moorman, +37 authors Erin M. Keast
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2016
TLDR
Clinicians and policy makers could use progression risk data in prioritization and in determining the timing of treatment for patients in early stages of liver disease in this cohort study of HCV patients identified from 4 integrated health systems in the United States. Expand
Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
TLDR
The TapHCV (treatment as prevention of hepatitis C virus) model is developed, an agent-based microsimulation model that projects the long-term benefits and costs of different HCV screening and treatment scenarios in U.S. prisons. Expand
Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
TLDR
Based on data from the Veteran Affairs Clinical Case Registry, statin use among patients with HCV and compensated cirrhosis is associated with a more than 40% lower risk of Cirrhosis decompensation and death. Expand
A proposed nationwide reporting system to satisfy the ethical obligation to prevent drug diversion-related transmission of hepatitis C in healthcare facilities.
  • Tim Lahey, W. Nelson
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2015
TLDR
A national centralized reporting system is proposed to support institutional fulfillment of the ethical obligation to protect the health of patients by preventing such nosocomial outbreaks. Expand
CLINICAL PRACTICE. Primary Care for Men Who Have Sex with Men.
  • T. Wilkin
  • Medicine
  • The New England journal of medicine
  • 2015
TLDR
Men who are at increased risk for HIV infection, especially those who have anal sex with multiple partners without the use of condoms, should be offered preexposure prophylaxis to reduce the risk of HIV acquisition. Expand
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
  • N. Khalaf, D. White, +5 authors H. El‐Serag
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2015
TLDR
A modest daily caffeine intake (as little as 100 mg) may protect against advanced hepatic fibrosis in men with chronic HCV infection, and additional research is needed to confirm these findings in women and in people with other chronic liver diseases. Expand
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
TLDR
Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.3% after 12 weeks of treatment and 76.0% after 8 weeks, respectively. Expand
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
TLDR
Among patients with genotype 3 HCV infection, including a large proportion of treatment-experienced patients with cirrhosis, the combination of sofosbuvir, peginterferon, and ribavirin for 12 weeks produces high rates of SVR. Expand
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
TLDR
Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease. Expand
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
TLDR
The goal of the hepatitis C guidance is to provide upto-date recommendations for HCV care practitioners on the optimal screening, management, and treatment for adults with HCV infection in the United States, using a rigorous review process to evaluate the best available evidence. Expand
...
1
2
3
4
5
...